drugset / Trial / NCT01134224
A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes
RandomizedCrossoverDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | biphasic insulin aspart 30 | Protein / enzyme biologic | 0.4 iu/kg | Subcutaneous |
| Comparator | biphasic insulin aspart 30 | Protein / enzyme biologic | 0.6 iu/kg | Subcutaneous |
| Comparator | biphasic insulin aspart 30 | Protein / enzyme biologic | 0.8 iu/kg | Subcutaneous |
| Subject | insulin degludec/insulin aspart | Unknown | 0.4 iu/kg | Subcutaneous |
| Subject | insulin degludec/insulin aspart | Unknown | 0.6 iu/kg | Subcutaneous |
| Subject | insulin degludec/insulin aspart | Unknown | 0.8 iu/kg | Subcutaneous |